Background/Aims: To evaluate the prognostic significance of monocytes and monocytic myeloid-derived suppressor cells (M-MDSCs) for patients with diffuse large B-cell lymphoma (DLBCL) under R-CHOP chemotherapy. Methods: Flow cytometry (FCM) was applied to measure M-MDSCs (CD14 + HLA-DR low/− M-MDSCs). Results: Analysis of 144 patients with DLBCL under R-CHOP treatment showed that the 5-year overall survival rate was 61.09% (95% CI: 43.72%-72.56%) and the average survival time of patients with monocytes (%) ≥ 8% was shorter than those with monocytes (%) < 8% (P = 0.0036). Further stratified analysis suggested that the average survival time of patients with monocytes (%) ≥ 8% was shorter than patients with monocytes (%) < 8% in the moderate outcome group (R-IPI = 1, 2) (P = 0.0168) and in the poorest outcome group (R-IPI > 2) (P = 0.0397), meanwhile, there was no significant difference in survival of patients with monocytes (%) ≥ 8% compared to patients with monocytes (%) < 8% in the best outcome group (R-IPI = 0) (P = 0.3106). Both of monocytes (%) and M-MDSCs were decreased in different R-IPI groups after 4-course of R-CHOP chemotherapy (P < 0.05). Conclusion: Our results indicated that monocytes (%) and M-MDSCs combined with R-IPI may be a simple and efficient immunological index to evaluate prognosis.
Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Introduction
Diffuse large B-cell lymphoma (DLBCL) is a mostly common type of malignant lymphoma, its morbidity is up to 30%-40% in non-Hodgkin's lymphoma (NHL) [1, 2] . The clinical presentation, pathomorphology, immunophenotype, therapeutic reaction and prognosis of DLBCL significantly varied [3] . The accurate pathologic diagnosis, type, stratification and prognostic indexes are useful to promote the efficacy for patients with DLBCL. It has been proved that R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristinesulfate, prednisone) chemotherapy improved the outcome of patients with DLBCL [2, [4] [5] [6] . Now revised international prognostic index (R-IPI) submitted by Sehn LH, et al in 2007 is widely used to identify the prognosis accurately for patients with DLBCL treated with R-CHOP in clinic [1] . Patients are divided into three groups according to R-IPI based on multiple clinical indexes: the best outcome group (R-IPI = 0), the moderate outcome group (R-IPI =1, 2) and the poorest outcome group (R-IPI > 2) [1] . Up to now, it's well known that the clinical progression and biologic characteristics of tumor is not only dependent on tumor malignancy, but also determined to the immunologic status and microenvironment of organism. The immunocytes including tumor invasive lymphocytes (TIL), tumor associated macrophages (TAM) and MDSCs play an important role in the tumor pathogenesis, and the related primary and secondary immunity may affect the efficacy and outcome of patients [7] [8] [9] [10] [11] . MDSCs were significantly elevated in pathological process and became a hot topic recently [12] . Long-term clinical studies showed that patients diagnosed lymphoma (Hodgkin lymphoma, follicular lymphoma (FL), DLBCL) with elevated peripheral absolute lymphocyte count (ALC) and absolute monocyte count (AMC) or low lymphocyte/monocyte ratio (LMR) tended to have worse survival and tumor progression [13] [14] [15] [16] [17] . However, the type and threshold of related immunocytes were different among different studies so that it is in doubt that the immunologic index could be a factor to identify prognosis in lymphoma. This study analyzed retrospective data from 144 patients with DLBCL under R-CHOP treatment in the Second Hospital of Lanzhou University. We measured peripheral monocytes (%) and M-MDSCs in patients with DLBCL at new diagnosis and after 4-course of R-CHOP chemotherapy, analyzed the variation of monocytes (%) and M-MDSCs pre and post-therapy, compared the survival time of patients with different monocytes (%) adjusted to R-IPI to investigate the prognostic significance of monocytes (%) and M-MDSCs in immunochemotherapy.
Materials and Methods
This study is approved by The Second Hospital of Lanzhou University Medical Ethics Committee. 
Patients
R-IPI score and treatment
All patients were divided into three groups according to R-IPI system. There were 21, 57 and 66 patients in the best outcome group (R-IPI = 0), the moderate outcome group (R-IPI = 1, 2) and the poorest outcome group (R-IPI > 2), respectively. All patients received standard R-CHOP chemotherapy, once every 21 days, received assessement every 2-course of chemotherapy. If the patient got CR (complete response) or PR (partially response) after receiving 4-course of chemotherapy, he/she would be treated for total 6 or 8 courses of chemotherapy, respectively. If the patient got SD (stable disease) or PD (progressive disease) after receiving 4-course of chemotherapy rescue therapy or second-line therapy (ESHAP, ICE, GDP, allo-BMT) would be taken for them.
Measurement of Monocytes and M-MDSCs
We collected 5 ml blood in heparinized tube from patients at initial diagnosis or after receiving 4-course of R-CHOP treatment. M-MDSCs was marked by CD14 + HLA-DR -/low and measured by FCM. Automatic blood cell analyzer was used to count and classify blood cells and the percent of monocytes in leukocytes (monocytes (%)) represented the detection of monocytes.
Statistical analysis
The data was analyzed by Stata12.0 software. The comparison of survival rate between different groups was done by log-rank test of Kaplan-Meier. The data got from pre and post-therapy was compared by matchedpair design and the D-value obeyed normal distribution. The simple relative factor r was used in correlation test. P < 0.05 was defined as statistical significance.
Results
Patient characteristics
All 144 patients with newly diagnosed DLBCL met the inclusion criteria were enrolled into this study. The median age was 61 years, aged from 20 to79 years. 89 patients (61.8%) were older than 60 years and other 55 patients (38.2%) were younger than or equal to 60 years. All patients were divided into two groups including 63 germinal center Table 1 . The baseline characteristics of patients with DLB-CL B-cell (GCB) patients and 81 non-germinal center B-cell (non-GCB) patients according to the Hans classification [18] . 86 cases (59.7%) are primary lymphoma and 58 cases (40.3%) are primary extranodal lymphoma. The lymph nodes had been invaded in 68.1% (98/144) cases, especially cervical lymph nodes invasion in 60.2% (59/98) cases. 50.7% (73/144) cases had extranodal invasion, especially bone marrow invasion in 67.1% (49/73) cases. All patients were subdivided into two groups according to monocytes (%): monocytes (%) ≥8% group and monocytes (%) < 8% group. (Table 1) After receiving 4-course of standard R-CHOP, 81 cases (56.3%), 40 cases (27.8%), 19 cases (13.2%) and 4 cases (2.8%) got CR, PR, SD and PD respectively. To the end point of follow-up, 26 patients (18.1%) died (5 cases died of treatment and 21 cases died of progressive disease), the median follow-up time was 37.4 months (ranged from 12.1 to 93.0 months) ( Table 2) .
Survival analysis of different subtypes and prognosis of patients
The follow-up data was analyzed by Kaplan-Meier. The 5-year overall survival was 61.09% (95%CI: 43.72%-72.56%) (Fig. 1) . Sub-group analysis showed that the mean survival time of non-GCB and GCB patient was 43.9 months (95%CI: 41.3-46.6 months) and 47.8 months (95%CI: 45.6-50.0 months) respectively and there was no significant difference (P = 0.1692) (Fig. 2A) . The mean survival time of patients in the best outcome group, (Fig. 2B) .
Effect of peripheral Monocytes (%) on survival of patients at new diagnosis
The normal value of monocytes (%) ranges from 3% to 8% in our hospital and the upper limit value (8%) was used as the threshold in this study. With R-IPI for the diagnostic criteria of prognosis and monocytes (%) for the result of prognostic diagnosis, AUC (area under the curve) was 0.8246 (95%CI: 0.7025-0.9466) and 0.7067 (95%CI: 0.6215-0.7919) in the moderate outcome group and poorest outcome group, respectively (Fig. 3A, 3B) . Meanwhile, there was no corresponding cutoff value in the best outcome group because of the irrelevance of monocytes (%). Patients were divided into two groups based on the value of monocytes (%). The mean survival time of patients newly diagnosed with monocytes(%) ≥ 8% was 42.3 months (95%CI: 39.3-45.2 months) while the mean survival time of patients with monocytes (%) < 8% was 48.6 months (95%CI: 46.6-50.6 months), and it was significantly different between these two groups (P = 0.0036) (Fig. 4A) . In the best outcome group consisting of 21 cases, the mean survival time between the group with monocytes (%) ≥ 8% 3 months) ) and the group with monocytes (%) < 8% (51.4 months (95%CI: 50.3-52.5 months)) was similar (P =0.3106) (Fig. 4B) . In the moderate outcome group consisting of 57 cases, the mean survival time in the group with monocytes (%) ≥ 8% (40.6 months (95%CI: 38.4-42.7 months)) was shorter compared to the group with monocytes (%) < 8% (44.8 months (95%CI: 43.5-46.1 months)) (P = 0.0168) (Fig. 4C) . In the poorest outcome group made up of 66 cases, the mean survival time in the group with monocytes (%) ≥ 8% (29.5 months (95%CI: 28.1-31.0 months)) was shorter than the group with monocytes (%) < 8% (35.9 months (95%CI: 29.9-36.9 months)) (P =0.0397) (Fig. 4D) . These results suggested that monocytes (%) may be a predictor for outcome of patients with DLBCL.
Comparison of peripheral monocytes (%) and M-MDSCs pre and post-therapy from different R-IPI groups
The data was analyzed from 144 patients with DLBCL pre-therapy and after 4-course of R-CHOP. We compared the variation of peripheral monocytes (%) in different groups based on R-IPI. In the best outcome group, the monocytes (%) after therapy (6.43%±1.25%(95%CI: 5.86%-6.70%)) was decreased significantly compared with those of pre-therapy (7.62%±1.53% (95%CI: 6.92%-8.32%)) (t = 5.294, P < 0.0001); In the moderate outcome group, the monocytes (%) after therapy (6.70% ± 1.65%(95%CI:6.27%-7.14%)) was decreased significantly compared with those of pre-therapy (7.65% ± 2.48% (95%CI: 6.99%-8.31%)) (t=5.4244, P < 0.0001); In the poorest outcome group, the monocytes (%) after therapy (9.18% ± 3.61% (95%CI: 8.29%-10.07%)) was decreased obviously compared with those of pre-therapy (10.39% ± 4.68% (95%CI: 9.24%-11.55%)) (t = 4.8403, P < 0.0001) ( Table 3) .
The variation of peripheral M-MDSCs pre-therapy and post-therapy was compared in different groups based on R-IPI. In the best outcome group, the M-MDSCs after therapy (6.98% ± 1.39% (95%CI: 6.35%-7.61%)) was decreased significantly compared with those of pretherapy (7.7% ± 1.35% (95%CI: 7.08%-8.32%)) (t = 3.1993, P = 0.0023); In the moderate outcome group, the M-MDSCs after therapy (7.90% ± 1.24% (95%CI: 7.57%-8.23%)) was The mean survival time among the best prognosis group, the moderate prognosis group and the poorest prognosis group was significantly different ( P < 0.0001). 
The correlation analysis of monocytes (%) and M-MDSCs in patients newly diagnosed or treated with R-CHOP
We tried to found the link of monocytes (%) and M-MDSCs in patients with DLBCL at new diagnosis or after 4-course of R-CHOP treatment by correlation analysis. The correlation analysis of peripheral monocytes (%) and M-MDSCs demonstrated that there was a positive correlation between peripheral monocytes (%) and M-MDSCs pre-therapy (r = 0.6172, P < 0.0001) or post-therapy (r = 0.7241, P < 0.0001) (Fig. 5) .
Discussion
With the application of molecular targeted drugs, the 10-year overall survival rate of patients with DLBCL with R-CHOP treatment was improved [19] [20] [21] . To date, R-CHOP chemotherapy is still the standard treatment for patients with DLBCL. Fu, K et al. showed that the 3-year OS of patients with DLBCL was improved after receiving R-CHOP chemotherapy (42% VS 77%, P < 0.001) and the prognosis of GCB patients was better than non-GCB patients (85% VS 69%, P = 0.032) [22] . However, it also demonstrated that there was no obviously different OS between GCB and non-GCB subtype patients with DLBCL who received R-CHOP chemotherapy [23] . Our results also suggested that the 5-year OS of patients with DLBCL who were treated with R-CHOP chemotherapy was 61.09% and the mean survival time was not related to the pathological subtypes (P = 0.1692). Prognostic indexes for lymphoma are very profitable to select best treatment for patients and improve their prognosis [24, 25] . A systematic review and meta-analysis enrolled 2643 patients demonstrated that low serum 25-hydroxyvitamin D levels can be a prognostic factor for patients with hematological cancer [26] . R-IPI is a better clinical prognostic index than international prognostic index (IPI) in patients with DLBCL [1] . R-IPI was applied to divide all patients with R-CHOP treatment into three groups and we found that the mean survival time among different prognostic groups was significantly different (P < 0.0001). It coincided with the results of study executed by Hong J. et al. [27] . These results suggested that immunochemotherapy (R-CHOP) could improve the efficacy for patients with DLBCL with poor prognosis and R-IPI is still an efficient prognostic index for patients with DLBCL in immunochemotherapy era.
The non-malignant immunocytes in tumor microenvironment play a vital role in tumor heterogeneity [28] . Single-factor analysis or multi-factor analysis showed that AMC and ALC both were the independent poor prognostic factor and both of them adjusted to R-IPI may identify the high-risk patients in DLBCL and FL [15, 17] . A multi-center study enrolled 1017 patients showed that AMC > 630 mm³ at diagnosis was a predictor to identify the high-risk patients in rituximab era [16] . During the period of R-CHOP treatment for patients with DLBCL, peripheral ALC/AMC ratio recovery may predict prognosis and ALC/AMC < 1.1 was an independent parameter of OS and PFS [29] . We found that peripheral AMC usually was normal but monocytes (%) usually elevated in DLBCL from previous studies. Thus, we used an automatic blood cell analyzer to count and classify blood cells, monocytes (%) represents Table 3 . Comparison of monocytes (%) and M-MDSCs pre-therapy and post-therapy the result of monocytes and its threshold is the upper limit value (8%) based on the normal value (3%-8%) in our hospital. Our study showed that the 5-year OS was 61.09% among 144 patients with newly diagnosed DLBCL with R-CHOP treatment and the survival time of patients with monocytes (%) ≥ 8% at new diagnosis was shorter than those with monocytes (%) < 8% in the poorest group and the moderate outcome group but not in the best outcome group based on R-IPI. ROC curves were done for the cutoff value of monocyte (%). In the best outcome group, there was no corresponding cutoff value because of the irrelevance of monocytes (%). In the moderate outcome group, AUC (area under the curve) was 0.8246 (95%CI: 0.7025-0.9466). The sensitivity is 94.74% and specificity is 66.67% when monocytes (%) ≥ 7%. The sensitivity is 54.39% and specificity is 80.95% when monocytes (%) ≥ 8%. Those results illustrated that the value of monocytes (%) of 8% had better prognostic value in the moderate outcome group. In the poorest outcome group, AUC was 0.7067 (95%CI: 0.6215-0.7919). The sensitivity is 60.61% and specificity is 55.13% when monocytes (%) ≥ 8%, and the 5-year OS and survival time of patients between the group with monocytes (%) ≥ 8% and the group with monocytes (%) < 8% are different. But when monocytes (%) ≥ 10%, the sensitivity is 54.55% and specificity is 83.88%. It indicated that the value of 10% as a threshold may be more valuable, which may result from other prognostic indexes have even bigger weight. Therefore, a further research with more patients and fine sorted stratification should be done to clarify the more proficient cutoff value of monocytes (%) directed against patients with poor prognosis. These results suggested that the peripheral monocytes (%) could predict prognosis as well as R-IPI, even that the elevation of monocytes (%) could be a better predictor to evaluate poor prognosis in the poorest and moderate outcome groups. Blood test as a clinical routine test is economic, convenient and easy. Therefore, it is very necessary to apply monocytes (%) combined with R-IPI to identify the high risk of patients with poor prognosis so that we could adjust the corresponding therapy in time to improve therapeutic effect.
MDSCs are a heterogeneous group of cells derived from immatureprecursor cells that could change immunological microenvironment through multiple pathways and promote progressive disease [30, 31] . Monocytic MDSCs (M-MDSC CD14 + HLA-DR -/low ) is one subtype of MDSCs. Previous studies showed that the elevation of monocytes expressing CD14 + HLA-DR -/low , TAM and tumor-associated MDSC all were related to the poor prognosis in different tumors including lymphoma [10, 32] . Tadmor et al. found that AMC of patients at new diagnosis may be related to M-MDSCs [33] . Monocytes (%) and M-MDSCs from different prognosis groups based on R-IPI significantly decreased after receiving 4-course of R-CHOP treatment compared to pre-therapy and there was significant difference in comparison of every two groups in our study. Our results indicated that monocytes and M-MDSCs may participate in the progression of DLBCL, R-CHOP could directly kill tumor cells and is related to immunity of organism. These findings may provide a new way to target monocytes (%) and M-MDSCs remedy and improve therapeutic effect for patients with DLBCL in the future. Correlation analysis showed that peripheral monocytes (%) was positively related to M-MDSCs at initial diagnosis or after 4-course of R-CHOP treatment, but the link of monocytes (%) and M-MDSCs still needs for further research. A further study enrolled more subjects should be done to investigate the derivation and function of M-MDSCs, the detailed link of monocytes (%) and M-MDSCs and prognostic significance in patients with DLBCL.
